Drug Trial Radar · NCT01138007
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Last checked: Nov 20, 2026Latest source record: Aug 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
572
Actual
Start
Jun 17, 2010
Primary completion
Aug 1, 2012
Study completion Aug 7, 2012
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 7, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study to confirm the efficacy of 323U66 Sustained Release (SR) orally administered to patients with MDD (Major Depressive Disorder) at doses level of 150 mg/day and 300 mg/day for 8 weeks based on the decrease in MADRS (Montgomery-Asberg Depression Rating Scale) total score, and to evaluate the safety based on adverse events, clinical laboratory tests and vital signs.
Conditions
- Depressive Disorder, Major
Interventions
323U66 SR 150 mg tabletDrug
323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
323U66 SR 150 mg placebo tabletDrug
323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/WithdrawalTime frame: Baseline and Week 8/Withdrawal
Locations
59 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukushima, Japan
GSK Investigational Site
Fukushima, Japan
GSK Investigational Site
Fukushima, Japan
GSK Investigational Site
Hiroshima, Japan
GSK Investigational Site
Hyōgo, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kumamoto, Japan
GSK Investigational Site
Kyoto, Japan
GSK Investigational Site
Nara, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Osaka, Japan
GSK Investigational Site
Saga, Japan
GSK Investigational Site
Saga, Japan
GSK Investigational Site
Saga, Japan
GSK Investigational Site
Saitama, Japan
GSK Investigational Site
Shizuoka, Japan
GSK Investigational Site
Tochigi, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.